Your browser doesn't support javascript.
loading
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
Takahashi, Naoto; Tauchi, Tetsuzo; Kitamura, Kunio; Miyamura, Koichi; Saburi, Yoshio; Hatta, Yoshihiro; Miyata, Yasuhiko; Kobayashi, Shinichi; Usuki, Kensuke; Matsumura, Itaru; Minami, Yosuke; Usui, Noriko; Fukuda, Tetsuya; Takada, Satoru; Ishikawa, Maho; Fujimaki, Katsumichi; Gomyo, Hiroshi; Sasaki, Osamu; Ohishi, Kohshi; Miyake, Takaaki; Imai, Kiyotoshi; Suzushima, Hitoshi; Mitsui, Hideki; Togitani, Kazuto; Kiguchi, Toru; Atsuta, Yoshiko; Ohtake, Shigeki; Ohnishi, Kazunori; Kobayashi, Yukio; Kiyoi, Hitoshi; Miyazaki, Yasushi; Naoe, Tomoki.
Afiliação
  • Takahashi N; Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, Akita, 010-8543, Japan. naotot@doc.med.akita-u.ac.jp.
  • Tauchi T; Department of Hematology, Tokyo Medical University, Tokyo Medical University, Tokyo, Japan.
  • Kitamura K; Division of Hematology, Ichinomiya Municipal Hospital, Ichinomiya, Japan.
  • Miyamura K; Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
  • Saburi Y; Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
  • Hatta Y; Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan.
  • Miyata Y; National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
  • Kobayashi S; Division of Hematology, National Defense Medical College, Tokorozawa, Japan.
  • Usuki K; Department of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
  • Matsumura I; Department of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.
  • Minami Y; Department of Hematology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Usui N; Department of Clinical Oncology/Hematology, The Jikei University School of Medicine, Tokyo, Japan.
  • Fukuda T; Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan.
  • Takada S; Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
  • Ishikawa M; Department of Hematology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Fujimaki K; Department of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
  • Gomyo H; Department of Hematology, Hyogo Cancer Center, Akashi, Japan.
  • Sasaki O; Department of Hematology, Miyagi Cancer Center, Natori, Japan.
  • Ohishi K; Department of Transfusion Medicine and Cell Therapy, Mie University Hospital, Tsu, Japan.
  • Miyake T; Department of Oncology/Hematology, Shimane University Hospital, Izumo, Japan.
  • Imai K; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Suzushima H; Department of Hematology, Kumamoto Shinto General Hospital, Kumamoto, Japan.
  • Mitsui H; Department of Hematology, Otemae Hospital, Osaka, Japan.
  • Togitani K; Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi, Japan.
  • Kiguchi T; Department of Hematology, Chugoku Central Hospital, Fukuyama, Japan.
  • Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
  • Ohtake S; Kanazawa University, Kanazawa, Japan.
  • Ohnishi K; Japanese Red Cross Aichi Blood Center, Seto, Japan.
  • Kobayashi Y; Hematology Division, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.
  • Kiyoi H; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Miyazaki Y; Department of Hematology, Nagasaki University, Nagasaki, Japan.
  • Naoe T; National Hospital Organization, Nagoya Medical Center, Nagoya, Japan.
Int J Hematol ; 107(2): 185-193, 2018 Feb.
Article em En | MEDLINE | ID: mdl-28929332
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Mieloide de Fase Crônica / Mesilato de Imatinib Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Int J Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão País de publicação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mielogênica Crônica BCR-ABL Positiva / Leucemia Mieloide de Fase Crônica / Mesilato de Imatinib Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Int J Hematol Assunto da revista: HEMATOLOGIA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão País de publicação: Japão